Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Eli Lilly

Pfizer’s Once‑Monthly GLP‑1 Shows Strong Weight Loss but Raises Dosing‑Safety Questions

Mid‑stage ADA data led Pfizer to plan slower dose escalation and an expanded Phase 3 program to test monthly dosing after trials showed meaningful weight loss with clustered gastrointestinal side effects.

35 ARTICLES

last mo.

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

27 ARTICLES

last mo.

New Trials Show Daily Pills Can Help Maintain Weight Loss After GLP-1 Injections

15 ARTICLES

2mo ago

Lilly’s Oral Foundayo Matches Insulin on Heart Safety in Major Diabetes Trial

55 ARTICLES

3mo ago

FDA Clears 7.2‑mg Wegovy as India Enters Generic Semaglutide Era

16 ARTICLES

3mo ago

Rocket Lab Lands $190 Million Hypersonic Test Deal, Lifts Backlog Past $2 Billion

18 ARTICLES

4mo ago

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

14 ARTICLES

6mo ago

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

15 ARTICLES

7mo ago

Lancet Phase 3 Trial Shows Oral GLP-1 Orforglipron Aids Weight Loss and Diabetes Control

7 ARTICLES

7mo ago

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises

32 ARTICLES

10mo ago

Lilly’s Orforglipron Pill Hits Phase 3 Goals, Clearing Path to Global Filings

54 ARTICLES

10mo ago

Lilly’s Oral GLP-1 Pill Underperforms Wegovy in Late-Stage Trial